A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

This randomized, double‐blind, double‐dummy, parallel‐group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta‐1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta‐1a SC three times per week; or interferon beta‐1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).